DDInter927 DDInter77
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys.
Amisulpride {u} (Compound) resembles {v} (Compound) Alizapride
Amisulpride {u} (Compound) binds {v} (Gene) HTR7
Amisulpride {u} (Compound) upregulates {v} (Gene) RGS2
Amisulpride {u} (Compound) causes {v} (Side Effect) Urticaria
Amisulpride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin Immune Fab (Ovine)
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Promethazine
Amisulpride {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Amisulpride (Compound) resembles Alizapride (Compound)
Amisulpride (Compound) binds HTR7 (Gene)
Amisulpride (Compound) upregulates RGS2 (Gene)
Amisulpride (Compound) causes Urticaria (Side Effect)
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Digoxin Immune Fab (Ovine)
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Amisulpride may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Promethazine
Amisulpride (Compound) resembles Metoclopramide (Compound) and Amisulpride may lead to a major life threatening interaction when taken with Metoclopramide